2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
42
Precursor Cell Lymphoblastic Leukemia-Lymphoma
33
Prostatic Neoplasms
32
Lymphoma, Large B-Cell, Diffuse
29
Lymphoma, Follicular
15
Leukemia
15
Lymphoma, Non-Hodgkin
13
Hodgkin Disease
11
Burkitt Lymphoma
10
Leukemia, Biphenotypic, Acute
8
Neoplasm Metastasis
7
Recurrence
6
Neoplasms
6
Lymphoma, Large-Cell, Anaplastic
6
Lymphoma, B-Cell
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Hemangioma
5
Ovarian Neoplasms
4
Multiple Myeloma
4
Immunoblastic Lymphadenopathy
4
Dendritic Cell Sarcoma, Interdigitating
4
Metastatic Castration-resistant Prostate Cancer
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, B-Cell, Marginal Zone
3
Breast Neoplasms
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Neurotoxicity Syndromes
2
Interventions
Cyclophosphamide
18
ofatumumab
14
fludarabine
12
Rituximab
11
ibrutinib
10
fludarabine phosphate
9
acalabrutinib
7
obinutuzumab
6
Lenalidomide
6
Bendamustine Hydrochloride
6
venetoclax
5
pirtobrutinib
4
Vincristine
4
Mesna
4
Melphalan
4
Immunotherapy, Adoptive
4
Whole-Body Irradiation
3
Mycophenolic Acid
3
Chlorambucil
3
Bortezomib
3
Alemtuzumab
3
spebrutinib
2
navitoclax
2
idelalisib
2
Tacrolimus
2
Tablets
2
Stem Cell Transplantation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
KW-2478
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
Prednisolone
×
Clear all
NCT03899337
2023-01-09
STELLAR
University of Birmingham
Phase 2
Recruiting
105 enrolled